PA8815201A1 - Compuestos heterociclicos - Google Patents

Compuestos heterociclicos

Info

Publication number
PA8815201A1
PA8815201A1 PA20098815201A PA8815201A PA8815201A1 PA 8815201 A1 PA8815201 A1 PA 8815201A1 PA 20098815201 A PA20098815201 A PA 20098815201A PA 8815201 A PA8815201 A PA 8815201A PA 8815201 A1 PA8815201 A1 PA 8815201A1
Authority
PA
Panama
Prior art keywords
compounds
same
heterociclical
heterociclical compounds
substitutes
Prior art date
Application number
PA20098815201A
Other languages
English (en)
Spanish (es)
Inventor
Gaul Christoph
Gerspacher Marc
Pissot Soldermann Carole
Holzer Philipp
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8815201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8815201A1 publication Critical patent/PA8815201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PA20098815201A 2008-02-06 2009-02-05 Compuestos heterociclicos PA8815201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08151137 2008-02-06

Publications (1)

Publication Number Publication Date
PA8815201A1 true PA8815201A1 (es) 2009-09-17

Family

ID=39739330

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098815201A PA8815201A1 (es) 2008-02-06 2009-02-05 Compuestos heterociclicos

Country Status (27)

Country Link
US (1) US8420657B2 (https=)
EP (1) EP2247591A1 (https=)
JP (1) JP5323095B2 (https=)
KR (2) KR101277823B1 (https=)
CN (1) CN101981036B (https=)
AR (1) AR070558A1 (https=)
AU (1) AU2009211338B2 (https=)
BR (1) BRPI0908433A2 (https=)
CA (1) CA2714177A1 (https=)
CL (1) CL2009000255A1 (https=)
CO (1) CO6321262A2 (https=)
CR (1) CR11614A (https=)
DO (1) DOP2010000242A (https=)
EA (1) EA017952B1 (https=)
EC (1) ECSP10010463A (https=)
IL (1) IL207224A0 (https=)
MA (1) MA32134B1 (https=)
MX (1) MX2010008719A (https=)
NI (1) NI201000137A (https=)
NZ (1) NZ587271A (https=)
PA (1) PA8815201A1 (https=)
PE (1) PE20091485A1 (https=)
SM (1) SMP201000104B (https=)
TW (1) TW200938202A (https=)
UY (1) UY31631A1 (https=)
WO (1) WO2009098236A1 (https=)
ZA (1) ZA201005338B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CN102014959B (zh) * 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
CN102482292B (zh) * 2009-04-23 2017-07-18 Abbvie 公司 5‑ht受体的调节剂和其使用方法
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
PE20121336A1 (es) * 2009-12-01 2012-11-03 Abbvie Inc Nuevos compuestos triciclicos
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
BR112012027803A2 (pt) 2010-04-30 2016-08-09 Cellzome Ltd compostos de pirazol como inibidores de jak
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US20130224110A1 (en) * 2010-09-16 2013-08-29 Cornell University Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
EP2780017A1 (en) * 2011-11-15 2014-09-24 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
CN102627646A (zh) * 2012-03-19 2012-08-08 苏州四同医药科技有限公司 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法
CN102633802B (zh) * 2012-04-11 2014-03-19 南京药石药物研发有限公司 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法
JP6114820B2 (ja) * 2012-05-14 2017-04-12 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
CN103059030B (zh) * 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
CN106458914B (zh) * 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物
JP6484253B2 (ja) 2014-05-01 2019-03-13 ノバルティス アーゲー Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物
EA032487B1 (ru) * 2014-05-01 2019-06-28 Новартис Аг Соединения и композиции в качестве агонистов toll-подобного рецептора 7
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
CN111484496B (zh) * 2019-01-29 2022-11-29 江苏开元药业有限公司 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途
JP7617030B2 (ja) 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
KR20220051351A (ko) * 2019-08-08 2022-04-26 비말란 바이오사이언스즈, 인크. Jak 억제제
GB201911868D0 (en) * 2019-08-19 2019-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP4027993A4 (en) * 2019-09-13 2023-09-20 The Broad Institute Inc. Cyclooxygenase-2 inhibitors and uses thereof
GB201914910D0 (en) * 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
WO2023036252A1 (zh) * 2021-09-08 2023-03-16 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN116813624B (zh) * 2023-06-29 2025-10-03 成都金瑞基业生物科技有限公司 一种jak2抑制剂的晶型及制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7917643B2 (en) * 1996-09-12 2011-03-29 Audible, Inc. Digital information library and delivery system
US20030074530A1 (en) * 1997-12-11 2003-04-17 Rupaka Mahalingaiah Load/store unit with fast memory data access mechanism
US6887224B2 (en) * 1998-06-15 2005-05-03 Ilse Rubio Close fitting leakage resistant feminine hygiene pad
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
EP1485390B1 (en) 2002-03-07 2008-10-08 F. Hoffman-la Roche AG Bicyclic pyridine and pyrimidine p38 kinase inhibitors
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
US7532909B2 (en) * 2003-10-15 2009-05-12 Nextel Communications Inc. System and method for providing dedicated paging channels for walkie-talkie services
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
AU2005298637B8 (en) * 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US20060122003A1 (en) * 2004-12-03 2006-06-08 Kim Jong H Portable golf swing position training aid kit
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
CA2596830A1 (en) * 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
US7749527B2 (en) 2005-05-24 2010-07-06 Wyeth Llc Gel compositions for control of ecto-parasites
WO2007042298A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
EP2385053B1 (en) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
EP2455382B1 (en) * 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8119643B2 (en) 2006-03-20 2012-02-21 Synta Pharmaceuticals Corp. Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
JP4861772B2 (ja) * 2006-08-28 2012-01-25 富士通株式会社 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20090033605A (ko) * 2007-10-01 2009-04-06 삼성전자주식회사 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치
WO2009070524A1 (en) 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US20090192176A1 (en) * 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

Also Published As

Publication number Publication date
CA2714177A1 (en) 2009-08-13
EA017952B1 (ru) 2013-04-30
KR20100119786A (ko) 2010-11-10
JP5323095B2 (ja) 2013-10-23
PE20091485A1 (es) 2009-10-26
UY31631A1 (es) 2009-09-30
DOP2010000242A (es) 2010-08-31
CO6321262A2 (es) 2011-09-20
TW200938202A (en) 2009-09-16
US20090203688A1 (en) 2009-08-13
KR20130066703A (ko) 2013-06-20
ZA201005338B (en) 2011-09-28
NZ587271A (en) 2012-03-30
EA201001242A1 (ru) 2011-08-30
CR11614A (es) 2010-09-06
AU2009211338B2 (en) 2011-12-15
CL2009000255A1 (es) 2009-08-14
ECSP10010463A (es) 2010-10-30
IL207224A0 (en) 2010-12-30
AR070558A1 (es) 2010-04-21
NI201000137A (es) 2011-09-29
KR101277823B1 (ko) 2013-07-15
JP2011511034A (ja) 2011-04-07
WO2009098236A1 (en) 2009-08-13
MA32134B1 (fr) 2011-03-01
US8420657B2 (en) 2013-04-16
CN101981036B (zh) 2013-09-04
SMAP201000104A (it) 2010-11-12
AU2009211338A1 (en) 2009-08-13
BRPI0908433A2 (pt) 2019-09-24
CN101981036A (zh) 2011-02-23
MX2010008719A (es) 2010-09-24
EP2247591A1 (en) 2010-11-10
SMP201000104B (it) 2011-09-09

Similar Documents

Publication Publication Date Title
PA8815201A1 (es) Compuestos heterociclicos
UY31838A (es) Derivados de quinoxalin- y quinolin-carboxamida
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CR20150326A (es) Inhibidores de autotaxina
UY32848A (es) Compuestos heterocíclicos de oxima
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
SV2011003855A (es) Heteroarilos sustituidos
ECSP14013215A (es) Compuestos novedosos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
CU20100158A7 (es) Pirrolo[2,3-d]pirimidinas y usos de las mismas como inhibidores de cinasa de tirosina
CL2009001005A1 (es) Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias.
UY32419A (es) Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y utilizacion como inhibidores de la met
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa
UY31030A1 (es) Compuestos
GT201500189A (es) Inhibidores de autotaxina